KR102707216B1 - 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법 - Google Patents

올리고뉴클레오타이드 조성물 및 이를 제조하는 방법 Download PDF

Info

Publication number
KR102707216B1
KR102707216B1 KR1020217033531A KR20217033531A KR102707216B1 KR 102707216 B1 KR102707216 B1 KR 102707216B1 KR 1020217033531 A KR1020217033531 A KR 1020217033531A KR 20217033531 A KR20217033531 A KR 20217033531A KR 102707216 B1 KR102707216 B1 KR 102707216B1
Authority
KR
South Korea
Prior art keywords
delete delete
group
substituted
compound
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217033531A
Other languages
English (en)
Korean (ko)
Other versions
KR20210130822A (ko
Inventor
프렘찬드란 에이치. 라미야
Original Assignee
제론 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제론 코포레이션 filed Critical 제론 코포레이션
Priority to KR1020237018801A priority Critical patent/KR20230088509A/ko
Publication of KR20210130822A publication Critical patent/KR20210130822A/ko
Application granted granted Critical
Publication of KR102707216B1 publication Critical patent/KR102707216B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217033531A 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법 Active KR102707216B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237018801A KR20230088509A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US61/987,396 2014-05-01
US201562151909P 2015-04-23 2015-04-23
US62/151,909 2015-04-23
KR1020167029996A KR102316282B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
PCT/US2015/028327 WO2015168310A1 (en) 2014-05-01 2015-04-29 Oligonucleotide compositions and methods of making the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167029996A Division KR102316282B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018801A Division KR20230088509A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Publications (2)

Publication Number Publication Date
KR20210130822A KR20210130822A (ko) 2021-11-01
KR102707216B1 true KR102707216B1 (ko) 2024-09-19

Family

ID=54359301

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217033531A Active KR102707216B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020167029996A Active KR102316282B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020237018801A Ceased KR20230088509A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020247031813A Pending KR20240144488A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020167029996A Active KR102316282B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020237018801A Ceased KR20230088509A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020247031813A Pending KR20240144488A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Country Status (34)

Country Link
US (6) US9796747B2 (enExample)
EP (2) EP4286519A3 (enExample)
JP (6) JP7040892B2 (enExample)
KR (4) KR102707216B1 (enExample)
CN (3) CN111228288B (enExample)
AP (1) AP2016009489A0 (enExample)
AU (3) AU2015253158B2 (enExample)
BR (1) BR112016025196B1 (enExample)
CA (1) CA2943888A1 (enExample)
CL (4) CL2016002749A1 (enExample)
DK (1) DK3137479T5 (enExample)
EA (1) EA034882B9 (enExample)
ES (1) ES2963740T3 (enExample)
FI (1) FI3137479T3 (enExample)
HR (1) HRP20231505T1 (enExample)
HU (1) HUE064289T2 (enExample)
IL (2) IL248044B (enExample)
JO (2) JOP20200257A1 (enExample)
LT (1) LT3137479T (enExample)
MA (1) MA63525B1 (enExample)
MX (2) MX382233B (enExample)
MY (2) MY196927A (enExample)
PE (1) PE20170147A1 (enExample)
PH (1) PH12016502080A1 (enExample)
PL (1) PL3137479T3 (enExample)
PT (1) PT3137479T (enExample)
RS (1) RS64860B1 (enExample)
SG (2) SG11201608226YA (enExample)
SI (1) SI3137479T1 (enExample)
SM (1) SMT202300405T1 (enExample)
TW (2) TWI712413B (enExample)
UA (1) UA126108C2 (enExample)
WO (1) WO2015168310A1 (enExample)
ZA (2) ZA201606624B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037166T2 (hu) 2004-07-02 2018-08-28 Geron Corp Védett 3'-amino-nukleozid monomerek szintézise
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
SMT202000389T1 (it) 2015-04-23 2020-09-10 Geron Corp Metodi di preparazione di polinucleotidi usando composizioni di sali cationici multivalenti
US11332489B2 (en) * 2017-07-10 2022-05-17 Geron Corporation Process for preparing imetelstat
EP4523681A1 (en) * 2019-10-28 2025-03-19 Geron Corporation Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making the same
EP4051252A4 (en) 2019-10-28 2023-12-06 Geron Corporation CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO -1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYL ETHER-PROPANE AND METHODS OF MANUFACTURE AND USE THEREOF
EP4089099A4 (en) * 2020-01-08 2024-07-24 Nitto Denko Corporation NUCLEIC ACID SYNTHESIS PROCESS USING SEGMENT AMIDITE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037691A1 (en) 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
WO2001018015A1 (en) 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
EP0462145B1 (en) 1989-03-07 1994-04-27 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JPH05505941A (ja) 1990-03-29 1993-09-02 ギリード　サイエンシズ　インコーポレーテッド オリゴヌクレオチド―輸送剤ジスルフィド結合体
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
ATE312175T1 (de) 1993-10-18 2005-12-15 Inst Medical W & E Hall Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
WO1995025814A1 (en) 1994-03-18 1995-09-28 Lynx Therapeutics, Inc. Oligonucleotide n3'→p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
DK0778842T3 (da) 1994-07-07 2006-03-20 Geron Corp Mammal telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
CN1165508A (zh) 1994-11-07 1997-11-19 海布里顿公司 利用3h-1,2-苯并二硫酚-3-1,1二氧化物合成35s-标记的寡核苷酸
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
WO2002077184A2 (en) * 2001-03-23 2002-10-03 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
WO2005023994A2 (en) 2003-09-09 2005-03-17 Geron Corporation Modified oligonucleotides for telomerase inhibition
HUE037166T2 (hu) 2004-07-02 2018-08-28 Geron Corp Védett 3'-amino-nukleozid monomerek szintézise
WO2006023880A2 (en) * 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
WO2006044956A1 (en) * 2004-10-18 2006-04-27 Codon Devices, Inc. Methods for assembly of high fidelity synthetic polynucleotides
US7998938B2 (en) 2005-04-15 2011-08-16 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
DK2898887T3 (en) 2006-10-30 2019-01-07 Geron Corp Combination of telomerase inhibitor and gemcitabine for the treatment of cancer
WO2008094640A2 (en) * 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037691A1 (en) 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
WO2001018015A1 (en) 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use
JP2009046483A (ja) * 1999-09-10 2009-03-05 Geron Corp オリゴヌクレオチドｎ３’→ｐ５’チオホスホルアミデート：それらの合成および使用

Also Published As

Publication number Publication date
KR20230088509A (ko) 2023-06-19
AU2022203273A1 (en) 2022-06-02
KR102316282B1 (ko) 2021-10-25
US20220306676A1 (en) 2022-09-29
CN111228288A (zh) 2020-06-05
TWI709406B (zh) 2020-11-11
JOP20200257A1 (ar) 2017-06-16
MX2021004932A (es) 2021-08-16
RS64860B1 (sr) 2023-12-29
KR20240144488A (ko) 2024-10-02
KR20210130822A (ko) 2021-11-01
TWI712413B (zh) 2020-12-11
FI3137479T3 (fi) 2023-11-28
AU2015253158A1 (en) 2016-10-20
EA034882B9 (ru) 2020-07-13
JP2017514479A (ja) 2017-06-08
JP7736489B2 (ja) 2025-09-09
EP3137479B1 (en) 2023-08-30
CL2018001212A1 (es) 2018-08-03
JP7308309B2 (ja) 2023-07-13
MY178617A (en) 2020-10-19
DK3137479T5 (da) 2024-10-14
US11739114B2 (en) 2023-08-29
EP3137479A4 (en) 2018-02-07
BR112016025196A2 (pt) 2017-12-12
IL248044A0 (en) 2016-11-30
IL248044B (en) 2019-08-29
BR112016025196B1 (pt) 2022-08-02
US20250011359A1 (en) 2025-01-09
HRP20231505T1 (hr) 2024-03-01
MY196927A (en) 2023-05-11
CN111228288B (zh) 2023-10-20
SI3137479T1 (sl) 2023-11-30
JP2021182946A (ja) 2021-12-02
ES2963740T3 (es) 2024-04-01
ZA202005857B (en) 2024-01-31
EP3137479A1 (en) 2017-03-08
EP4286519A2 (en) 2023-12-06
CN106459134B (zh) 2020-02-18
US20240150391A1 (en) 2024-05-09
CL2018001213A1 (es) 2018-08-03
US20150337314A1 (en) 2015-11-26
CN106459134A (zh) 2017-02-22
CA2943888A1 (en) 2015-11-05
SMT202300405T1 (it) 2024-01-10
AU2020201707A1 (en) 2020-03-26
AP2016009489A0 (en) 2016-10-31
AU2015253158B2 (en) 2019-12-12
JP2018131453A (ja) 2018-08-23
MX2016014178A (es) 2017-05-04
MA63525B1 (fr) 2025-02-28
NZ763996A (en) 2021-03-26
ZA201606624B (en) 2020-12-23
PE20170147A1 (es) 2017-04-12
US20180016294A1 (en) 2018-01-18
TW201622732A (zh) 2016-07-01
PH12016502080A1 (en) 2017-01-09
JP7040892B2 (ja) 2022-03-23
HUE064289T2 (hu) 2024-02-28
MX382233B (es) 2025-03-13
EP4286519A3 (en) 2024-02-28
PT3137479T (pt) 2023-11-30
DK3137479T3 (da) 2023-11-20
MA63525A1 (fr) 2024-09-30
CN117357548A (zh) 2024-01-09
WO2015168310A1 (en) 2015-11-05
IL268570A (en) 2019-09-26
SG11201608226YA (en) 2016-10-28
US10392418B2 (en) 2019-08-27
JP2023073510A (ja) 2023-05-25
JP2022044679A (ja) 2022-03-17
LT3137479T (lt) 2023-10-10
AU2020201707B2 (en) 2022-02-17
US11299511B2 (en) 2022-04-12
EA201691786A1 (ru) 2017-04-28
NZ724764A (en) 2021-02-26
KR20160147768A (ko) 2016-12-23
PL3137479T3 (pl) 2024-02-26
SG10201911086XA (en) 2020-01-30
CL2016002749A1 (es) 2017-04-28
CL2022000202A1 (es) 2023-02-10
JO3767B1 (ar) 2021-01-31
JP2020050670A (ja) 2020-04-02
US9796747B2 (en) 2017-10-24
EA034882B1 (ru) 2020-04-01
US20180016293A1 (en) 2018-01-18
TW202017574A (zh) 2020-05-16
UA126108C2 (uk) 2022-08-17
IL268570B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
JP7736489B2 (ja) オリゴヌクレオチド組成物及びその作製方法
HK40104434A (en) Oligonucleotide compositions and methods of making the same
HK40030910A (en) Oligonucleotide compositions and methods of making the same
HK1231885B (en) Oligonucleotide compositions and methods of making the same
HK1231885A1 (en) Oligonucleotide compositions and methods of making the same
OA18106A (en) Oligonucleotide compositions and methods of making the same
OA19860A (en) Oligonucleotide compositions and methods of making the same.
EA044343B1 (ru) Неочищенная композиция полинуклеотидного соединения

Legal Events

Date Code Title Description
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211018

Application number text: 1020167029996

Filing date: 20161026

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211227

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220830

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220830

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220426

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20211018

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230104

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221128

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220830

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220426

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20211227

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20211018

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20230602

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230104

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20220830

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101001184

Request date: 20230602

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101001184; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230602

Effective date: 20240430

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20240430

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230602

Decision date: 20240430

Appeal identifier: 2023101001184

PS0901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20240618

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20240503

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240911

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240912

End annual number: 3

Start annual number: 1

PG1601 Publication of registration